PDF(Pubmed)
Abstract：
Lung and hematopoietic stem cell transplantation are therapeutic modalities in chronic pulmonary and hematological diseases, respectively. One of the complications in these patients is the development of bronchiolitis obliterans syndrome (BOS). The efficacy and safety of available treatment strategies in BOS remain a challenge. A few mechanisms have been recognized for BOS in lung transplant and graft-versus-host disease (GVHD) patients involving the TH-1 and TH-2 cells, NF-kappa B, TGF-b, several cytokines and chemokines, and cysteinyl leukotrienes (CysLT). Montelukast is a highly selective CysLT receptor antagonist that has been demonstrated to exert anti-inflammatory and anti-fibrotic effects in abundant experiments. One area of interest for the use of montelukast is lung transplants or GVHD-associated BOS. Herein, we briefly review data regarding the mechanisms involved in BOS development and montelukast administration as a treatment modality for BOS, and finally, the possible relationship between CysLTs antagonism and BOS improvement will be discussed.
A review of the therapeutic potential and possible mechanism of Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic stem cell transplantationLung and bone marrow transplantation are therapeutic modalities in chronic diseases of the lungs and the blood, respectively. One of the complications in these patients is the development of Bronchiolitis obliterans syndrome (BOS). The efficacy and safety of available treatment strategies in BOS remain a challenge. A few mechanisms for BOS in lung transplant and graft-versus-host disease (GVHD) patients involving many immune components have been recognized. Cysteinyl leukotrienes are products of plasma membrane phospholipids that increase smooth muscle contraction, microvascular permeability, and airway mucus secretion. Montelukast is a highly selective cysteinyl leukotriene receptor blocker demonstrated to exert anti-inflammatory and anti-fibrotic effects. One area of interest for the use of montelukast is in lung transplant- or GVHD-associated BOS. In this article, we briefly review data regarding the mechanisms involved in BOS development and montelukast administration as a treatment modality for BOS. Finally, the possible relationship between cysteinyl leukotriene inhibition and BOS improvement will be discussed.
A review of the therapeutic potential and possible mechanism of Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic stem cell transplantationLung and bone marrow transplantation are therapeutic modalities in chronic diseases of the lungs and the blood, respectively. One of the complications in these patients is the development of Bronchiolitis obliterans syndrome (BOS). The efficacy and safety of available treatment strategies in BOS remain a challenge. A few mechanisms for BOS in lung transplant and graft-versus-host disease (GVHD) patients involving many immune components have been recognized. Cysteinyl leukotrienes are products of plasma membrane phospholipids that increase smooth muscle contraction, microvascular permeability, and airway mucus secretion. Montelukast is a highly selective cysteinyl leukotriene receptor blocker demonstrated to exert anti-inflammatory and anti-fibrotic effects. One area of interest for the use of montelukast is in lung transplant- or GVHD-associated BOS. In this article, we briefly review data regarding the mechanisms involved in BOS development and montelukast administration as a treatment modality for BOS. Finally, the possible relationship between cysteinyl leukotriene inhibition and BOS improvement will be discussed.
摘要：
肺和造血干细胞移植是慢性肺部和血液系统疾病的治疗方法。分别。这些患者的并发症之一是闭塞性细支气管炎综合征（BOS）的发展。BOS可用治疗策略的有效性和安全性仍然是一个挑战。已经认识到肺移植和移植物抗宿主病（GVHD）患者中BOS的一些机制，涉及TH-1和TH-2细胞，NF-κB,TGF-b,几种细胞因子和趋化因子，和半胱氨酰白三烯（CysLT）。孟鲁司特是一种高度选择性的CysLT受体拮抗剂，已在大量实验中证明其具有抗炎和抗纤维化作用。使用孟鲁司特的一个感兴趣的领域是肺移植或GVHD相关的BOS。在这里，我们简要回顾了有关BOS发展和孟鲁司特给药作为BOS治疗方式的机制的数据，最后，将讨论CysLTs拮抗作用与BOS改善之间的可能关系。
孟鲁司特在治疗肺和造血干细胞移植后闭塞性细支气管炎综合征中的治疗潜力和可能机制的综述肺和骨髓移植是肺和血液慢性疾病的治疗方式，分别。这些患者的并发症之一是闭塞性细支气管炎综合征（BOS）的发展。BOS可用治疗策略的有效性和安全性仍然是一个挑战。已经认识到涉及许多免疫成分的肺移植和移植物抗宿主病（GVHD）患者中BOS的几种机制。半胱氨酰白三烯是增加平滑肌收缩的质膜磷脂的产物，微血管通透性,和气道粘液分泌。孟鲁司特是一种高度选择性的半胱氨酰白三烯受体阻断剂，具有抗炎和抗纤维化作用。使用孟鲁司特的一个感兴趣的领域是在肺移植或GVHD相关的BOS中。在这篇文章中,我们简要回顾了有关BOS发展和孟鲁司特作为BOS治疗方式所涉及的机制的数据.最后,将讨论半胱氨酰白三烯抑制与BOS改善之间的可能关系。
孟鲁司特在治疗肺和造血干细胞移植后闭塞性细支气管炎综合征中的治疗潜力和可能机制的综述肺和骨髓移植是肺和血液慢性疾病的治疗方式，分别。这些患者的并发症之一是闭塞性细支气管炎综合征（BOS）的发展。BOS可用治疗策略的有效性和安全性仍然是一个挑战。已经认识到涉及许多免疫成分的肺移植和移植物抗宿主病（GVHD）患者中BOS的几种机制。半胱氨酰白三烯是增加平滑肌收缩的质膜磷脂的产物，微血管通透性,和气道粘液分泌。孟鲁司特是一种高度选择性的半胱氨酰白三烯受体阻断剂，具有抗炎和抗纤维化作用。使用孟鲁司特的一个感兴趣的领域是在肺移植或GVHD相关的BOS中。在这篇文章中,我们简要回顾了有关BOS发展和孟鲁司特作为BOS治疗方式所涉及的机制的数据.最后,将讨论半胱氨酰白三烯抑制与BOS改善之间的可能关系。
